Skip to content

Study · Animal study (in vivo) · mouse · 2009

3 results

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I

Neurobiology of disease2 Mar 2009Cited by 93 (Europe PMC)

PMID19264130 (opens in a new tab)DOI10.1016/j.nbd.2009.02.011 (opens in a new tab)PepBankPUB-19264130
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In tau-transgenic mice, NAP increased Morris water maze performance compared with controls.

    In plain wordsIn mice with mutant human tau, NAP improved maze performance compared with controls.

    Peptide
    Davunetide
    Outcome
    IncreaseMorris water maze performance
    Study

    mousen: not reported in source

    Human double-mutant tau transgenic mice
    Comparator
    Controls
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · Approximately 5 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Results showed increased performance in the NAP-treated mice compared to controls, as demonstrated in the Morris water maze, (p<0.05).
    1 context sentence
    Summary · context
    Transgenic mice (2-month-old) that express the human double mutant tau protein [P301S;K257T] fused to the tau promoter, were subjected to daily intranasal drug treatment for approximately 5 months.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In tau-transgenic mice, NAP increased heat-stable soluble tau content compared with vehicle controls.

    In plain wordsIn mice with mutant human tau, NAP increased soluble tau compared with vehicle.

    Peptide
    Davunetide
    Outcome
    IncreaseHeat-stable soluble tau content
    Study

    mousen: not reported in source

    Human double-mutant tau transgenic mice
    Comparator
    Vehicle controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · Approximately 5 months followed by 5 additional monthsAs given in this study (mouse).

    Source sentences

    Summary
    Protein extraction identified increased tau protein content in the heat-stable soluble fraction, which contains microtubule-associated tau, in the 1-year-old NAP-treated mice as compared to vehicle-controls.
    2 context sentences
    Summary · context
    Treatment continued for 5 additional months and mouse cortices were biochemically analyzed.
    Summary · context
    Transgenic mice (2-month-old) that express the human double mutant tau protein [P301S;K257T] fused to the tau promoter, were subjected to daily intranasal drug treatment for approximately 5 months.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In tau-transgenic mice, NAP significantly reduced tau phosphorylation at Ser 202.

    In plain wordsIn mice with mutant human tau, NAP reduced tau phosphorylation at Ser 202.

    Peptide
    Davunetide
    Outcome
    DecreaseTau Ser 202 phosphorylation
    Study

    mousen: not reported in source

    Human double-mutant tau transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · Approximately 5 months followed by 5 additional monthsAs given in this study (mouse).

    Source sentences

    Summary
    Tau phosphorylation (Ser 202) increased in the tau-transgenic mice compared to control mice, and was significantly reduced in NAP-treated mice.
    2 context sentences
    Summary · context
    Treatment continued for 5 additional months and mouse cortices were biochemically analyzed.
    Summary · context
    Transgenic mice (2-month-old) that express the human double mutant tau protein [P301S;K257T] fused to the tau promoter, were subjected to daily intranasal drug treatment for approximately 5 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01056965

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

University of California, San Franciscon = 12Jan 2010 to Dec 2012

Predicted Tauopathies, Including · Progressive Supranuclear Palsy · Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17 · Corticobasal Degeneration Syndrome · Progressive Nonfluent Aphasia

Trial pageClinicalTrials.govUpdated 5 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.